Research workbench
Crystal structure of human arginase I in complex with 2- aminohomohistidine
Analyse Crystal structure of human arginase I in complex with 2- aminohomohistidine in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.
- PDB
- 3MFV
- Type
- protein
- Length
- 626 residues
- Chains
- 2
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Arginase-1
- EC
- 3.5.3.1
- UniProt
- P05089
- Ligands
- Z70, MN
- Pockets
- 4 · best druggability 0.77
Structure
x-ray diffraction · 1 distinct chain · 42% helix, 17% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A, B | Arginase-1 (EC 3.5.3.1) | protein | 313 | 42% helix, 17% strand | P05089 |
Ligands and binding sites
- Z70 · (2S)-2-amino-4-(2-amino-1H-imidazol-5-yl)butanoic acid · ligand · 2 copies · chains A, B
- MN · Manganese (II) ion · metal · 4 copies · chains A, B
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
4 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 1008 | 0.77 | 0.79 | 94 | Z70 |
| 2 | 87 | 0.41 | 0.79 | 20 | Z70 |
| 3 | 58 | 0.36 | 0.78 | 14 | empty |
| 4 | 63 | 0.32 | 0.76 | 16 | empty |
Interfaces
1 interface between chains.
- A–B · 498 Ų buried · 4 hydrogen bonds · protein-protein
Compared structures
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt P05089
- Elsewhere: RCSB PDB 3MFV · PDBe 3MFV · UniProt P05089
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.